Integrated Competitors

INBP -  USA Stock  

USD 1.09  0.03  2.83%

Integrated Biopharma competes with Aadi Biosciences, Abeona Therapeutics, Arca Biopharma, Acumen Pharmaceuticals, and Arbutus Biopharma; as well as few others. The company conducts business under Consumer Defensive sector and is part of Packaged Foods industry. Analyzing Integrated Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Integrated Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Integrated Biopharma competition on your existing holdings. Please see Integrated Biopharma Correlation with its peers.

Integrated Competition 

As of 20th of October 2021, Return on Average Assets is likely to drop to 0.26. In addition to that, Return on Average Equity is likely to drop to 0.72. Integrated Biopharma Tax Assets are very stable at the moment as compared to the past year. Integrated Biopharma reported last year Tax Assets of 3.27 Million. As of 20th of October 2021, Tangible Assets Book Value per Share is likely to grow to 0.86, while Total Assets are likely to drop about 23.6 M.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Integrated Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Integrated Biopharma in the context of predictive analytics.
LowEstimated ValueHigh
LowReal ValueHigh
LowNext ValueHigh
Band Projection (param)
LowerMiddle BandUpper
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Integrated Biopharma. Your research has to be compared to or analyzed against Integrated Biopharma's peers to derive any actionable benefits. When done correctly, Integrated Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Integrated Biopharma.

Integrated Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Integrated Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Integrated and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Integrated Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Integrated Biopharma Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Integrated Biopharma stock performing well and Integrated Biopharma company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Integrated Biopharma's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
At Risk
 2.17 (0.37)  0.00 (4.58)  0.00 (0.18)  0.00  3.73 (4.65)  14.81 
 2.10 (1.42)  0.00 (2.33)  0.00 (0.55)  0.00  2.25 (4.55)  12.04 
 1.55 (0.30)  0.00  0.85  0.00 (0.27)  0.00  4.36 (2.77)  8.11 
 5.00 (0.03)  0.08  0.18  3.94  0.0435 (14.33)  9.53 (7.50)  44.78 
 2.67 (0.46)  0.00 (0.18)  0.00 (0.11)  0.00  3.80 (7.66)  12.92 
 2.04 (0.26)  0.00 (0.16)  0.00 (0.11)  0.00  2.50 (4.53)  8.52 
 4.69  0.60  0.03 (0.25)  4.99  0.0209 (7.71)  10.16 (5.71)  37.88 
 1.54  0.11  0.04  0.31  1.75  0.0394 (1.68)  2.78 (2.48)  9.19 
 2.26 (0.15)  0.00 (2.46)  0.00 (0.07)  0.00  3.19 (5.45)  25.78 
 3.33  1.19  0.27 (10.22)  2.75  0.22 (4.08)  8.67 (3.83)  15.41 

Cross Equities Net Income Analysis

Select Fundamental

(31.4 K)(31.4 K)(31.4 K)(31.4 K)(31.4 K)(31.4 K)(17 M)(21.4 M)(10.4 M)(23.3 M)(4.3 M)(4.7 M)
(10.5 M)(10.5 M)(10.5 M)4.4 M(26.8 M)(14.5 M)(21.9 M)(27.3 M)(56.7 M)(76.3 M)(84.2 M)(86.5 M)
(8.4 M)(5.4 M)(4.3 M)(6.9 M)(9.7 M)(11.4 M)(16.4 M)(18.5 M)(7.9 M)(5.5 M)(9.7 M)(10.5 M)
(750 K)(345 K)(1.1 M)(788 K)(490 K)(333 K)(345 K)(545 K)(1 M)(681 K)(796 K)(858.8 K)
(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.3 M)(7.9 M)
(12.4 M)(10.1 M)29.6 M(14.1 M)(38.8 M)(62.7 M)(384.2 M)(84.4 M)(57.1 M)(153.7 M)(63.7 M)(68.8 M)
(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(3.6 M)(9.8 M)(10.6 M)
15.1 M(22.8 M)(20.8 M)(37.9 M)(92.5 M)(164.4 M)(271.4 M)(289.4 M)(245.2 M)(235.3 M)(281.6 M)(289 M)
(5.5 M)(6 M)(8.9 M)(16.7 M)(15.1 M)(12 M)(6.7 M)(14.2 M)(21.3 M)(29.4 M)(22.9 M)(24.7 M)
(33.8 M)(33.8 M)(33.8 M)(33.8 M)(33.8 M)(33.8 M)(33.8 M)(33.8 M)(9.3 M)(28.1 M)(36.7 M)(39.6 M)

Integrated Biopharma and related stocks such as Aadi Biosciences, Abeona Therapeutics, Arca Biopharma, Amer Bio Medica, Acumen Pharmaceuticals, Arbutus Biopharma, Abvc Biopharma, Acadia Pharmaceutica, Acer Therapeutics, and Adicet Bio Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Integrated Biopharma financial statement analysis. It represents the amount of money remaining after all of Integrated Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Integrated Biopharma Competitive Analysis

The better you understand Integrated Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Integrated Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Integrated Biopharma's competition over several years is one of the best ways to analyze its investment potential.
 Better Than Average     
 Worse Than Peers    View Performance Chart
Aadi Biosciences
Arca Biopharma
Amer Bio
Abvc Biopharma
Acer Therapeutics
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
Operating Margin
Current Valuation
Cash Flow from Operations
Retained Earnings
Current Asset
Five Year Return
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Last Dividend Paid
Short Ratio
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Potential Upside
Treynor Ratio
Maximum Drawdown
Market Risk Adjusted Performance
Risk Adjusted Performance
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Integrated Biopharma Competition Performance Charts

Complement your Integrated Biopharma position

In addition to having Integrated Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Top Penny Thematic Idea Now

Top Penny
Top Penny Theme
Solid stocks, funds or ETFs with above average market capitalization and strong fundamental indicators based on Macroaxis rating system. Top Penny theme has 21 constituents.
View All  Next Launch Top Penny
Please see Integrated Biopharma Correlation with its peers. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.